Mounjaro differs in its mechanism of action from existing GLP-1 receptor agonists in that it acts on two types of hormones, GIP and GLP-1, at the same time. In recent years, GLP-1 receptor agonists (GLP-1 RAs) have attracted attention as drug therapy for obesity and type 2 diabetes. Among them, Mounjaro has been reported to show a distinctive mechanism of action and clinical effects compared with other GLP-1 receptor agonists. This article summarizes and explains Mounjaro’s mechanism of action, its effects on weight loss and blood sugar improvement, how it differs from other GLP-1 receptor agonists, and the evidence from clinical trials.
Key points firstShort on time? Just read this part
- Mounjaro is the first dual-acting injectable medication in Japan that binds to two receptors, GIP and GLP-1
- Mounjaro’s action is made up of four pathways: glucose-dependent stimulation of insulin secretion, suppression of glucagon, delayed gastric emptying, and appetite suppression
- A key feature of Mounjaro is its high weight loss effect, owing to the addition of GIP action
What you will learn in this article
- How Mounjaro’s action differs from other GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide)
- How Mounjaro acts on both GIP and GLP-1
- Evidence from clinical trials on weight loss and blood sugar improvement
- Points to keep in mind when choosing Mounjaro
What are GLP-1 receptor agonists?
GLP-1 receptor agonists are medications that mimic the action of a hormone that curbs the rise in blood sugar after meals, and they are involved in both improving blood sugar and suppressing appetite. GLP-1 (glucagon-like peptide-1) is a hormone secreted from the intestine that helps regulate blood sugar after eating. GLP-1 lowers blood sugar through the following actions.
- Promoting insulin secretion from pancreatic beta cells (glucose-dependent)
- Suppressing glucagon secretion from pancreatic alpha cells
- Increasing the feeling of fullness by delaying gastric emptying
- Acting on areas of the brain involved in appetite regulation
Key point
Based on these actions, GLP-1 receptor agonists have been applied to the treatment of obesity and type 2 diabetes.
What is Mounjaro?
Mounjaro is the first dual-acting injectable medication in Japan that binds to two receptors, GIP and GLP-1. Mounjaro is a medication that acts on the receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, and it can be given as a once-weekly subcutaneous injection. In Japan it is approved as a medication for type 2 diabetes, and it is also attracting attention for its high weight loss effect.
The main features of Mounjaro are as follows.
Dual GIP/GLP-1 receptor agonist
Binds to two types of receptors and promotes insulin secretion in a glucose-dependent manner
Appetite suppression
Clinical trials have reported that its appetite suppression and increase in fullness are stronger than with single GLP-1 drugs
Long-acting
Maintains stable blood levels with once-weekly dosing
Mounjaro’s mechanism of action
Mounjaro’s action is made up of four pathways: glucose-dependent stimulation of insulin secretion, suppression of glucagon, delayed gastric emptying, and appetite suppression. Like conventional GLP-1 receptor agonists, Mounjaro promotes glucose-dependent insulin secretion and suppresses glucagon. In addition, the major difference from other drugs is that by also acting on GIP receptors at the same time, it has been shown in clinical trials to have stronger appetite suppression and weight loss effects than GLP-1-only drugs.
3-1. Promoting insulin secretion and improving blood sugar
Mounjaro binds to GLP-1 and GIP receptors on pancreatic beta cells and activates intracellular signaling pathways to increase insulin secretion. Because this is glucose-dependent, another advantage is a low risk of hypoglycemia when used alone.
3-2. Suppressing glucagon
It acts on pancreatic alpha cells to suppress glucagon secretion, curbing glucose production (gluconeogenesis) in the liver and thereby limiting the rise in blood sugar.
3-3. Increased fullness through delayed gastric emptying
By delaying gastric emptying, it curbs the rise in blood sugar after meals and keeps you feeling full for longer. This action is directly linked to appetite suppression and enhances the weight loss effect.
3-4. Action on areas of the brain involved in appetite regulation
GLP-1 and GIP receptors are thought to also exist in areas of the brain involved in regulating appetite, such as the hypothalamus and the medulla oblongata. Mounjaro is thought to act on the appetite center through these receptors and reduce food intake. Clinical data such as the SURPASS-2 trial suggest that this central action is stronger than with GLP-1-only drugs, but the detailed mechanism is still being studied.
Differences from other GLP-1 receptor agonists
GLP-1 receptor agonists include liraglutide, semaglutide and dulaglutide, and Mounjaro is distinguished from these by whether or not it has GIP action. The main differences compared with Mounjaro are as follows.
| Medication | Dosing frequency | Weight loss effect (clinical trials) | Features of action | Blood sugar improvement |
|---|---|---|---|---|
| Mounjaro | Once weekly | About 15–21% (SURMOUNT-1) | Dual GIP + GLP-1 action | High |
| Liraglutide | Daily | About 5–10% (SCALE trial) | GLP-1 action only | High |
| Semaglutide | Once weekly | Around 15% (STEP 1 trial) | GLP-1 action only | High |
| Dulaglutide | Once weekly | A few percent (mainly focused on blood sugar improvement) | GLP-1 action only | High |
- A key feature of Mounjaro is its high weight loss effect, owing to the addition of GIP action.
- Other drugs also have strong blood sugar–improving effects, but they differ in the degree of appetite suppression and weight loss.
Why not start by consulting online about the GLP-1 treatment that’s right for you?
*This is self-pay treatment. Effects and side effects vary from person to person.
Mounjaro’s effects in clinical trials
Mounjaro’s effects have been verified in two series of trials: the SURMOUNT trials in patients with obesity and the SURPASS trials in patients with type 2 diabetes. Many clinical trials of Mounjaro have been conducted in patients with obesity and patients with type 2 diabetes.
5-1. Weight loss effect
- The SURMOUNT-1 trial (Jastreboff AM, N Engl J Med, 2022;387:205-216) reported an average weight loss of 7–21% after 72 weeks of treatment, depending on dose (15.0% in the 5 mg group, 19.5% in the 10 mg group, 20.9% in the 15 mg group, and 3.1% in the placebo group)
- Shows a significant weight loss effect even in patients with obesity with a BMI of 30 or more
- The effect is further enhanced when combined with dietary management and exercise therapy
5-2. Blood sugar improvement effect
- The SURPASS-2 trial (Frías JP, N Engl J Med, 2021;385:503-515) reported HbA1c reductions of about 2.01–2.30%, depending on dose
- Because it promotes insulin secretion in a glucose-dependent manner, the risk of hypoglycemia when used alone is low
- The improvement is especially marked in patients with high blood sugar
5-3. Safety
- The main side effects are gastrointestinal symptoms such as nausea, constipation and diarrhea
- Severe hypoglycemia and pancreatitis are rare
- Research on the effects of long-term use on cardiovascular events is ongoing
Mounjaro side effects: types, frequency and how to manage them, explained by a doctor
The bottom line firstShort on time? Just read this partMounjaro’s side ...Weight loss strategies using Mounjaro
To get the effects of Mounjaro safely, three foundations are essential: reviewing lifestyle habits, managing self-injections and regular follow-up. Mounjaro has a weight loss effect even when used alone, but keeping the following points in mind allows you to use it more safely and effectively.
Combine with lifestyle improvements
Continuing a nutritionally balanced diet and exercise therapy maximizes the weight loss effect
Managing once-weekly self-injections
The dosing schedule is simple, improving long-term adherence
Regular medical follow-up
Check blood sugar, weight and side effects regularly with your doctor
Setting a target weight
It is important to set realistic and safe weight loss goals based on BMI and body fat percentage. Rapid weight loss can lead to feeling unwell or nutritional deficiencies. Because Mounjaro has a strong appetite-suppressing effect, it allows safe weight management while supporting a natural reduction in food intake.
Dealing with side effects
If gastrointestinal symptoms appear, it is possible to continue by consulting your doctor about adjusting the dose and making changes to what you eat. Nausea and constipation may appear especially at the start, but in many cases they ease over time.
Possibility of combination therapy
Mounjaro can be used together with other diabetes or obesity medications, but care is needed regarding drug interactions and the risk of hypoglycemia. Combined use is premised on being under a doctor’s guidance.
Comparative studies of Mounjaro and GLP-1 receptor agonists
In the SURPASS-2 trial, which directly compared Mounjaro with semaglutide, Mounjaro showed greater results in both HbA1c reduction and weight loss. In recent years, Mounjaro has also shown significant weight loss effects in comparative trials with existing GLP-1 receptor agonists.
Weight loss rate
- Mounjaro group in the SURMOUNT-1 trial: average reduction of 15–21% over 72 weeks
- Liraglutide group (SCALE trial): average reduction of 5–10%
Appetite suppression effect
Because Mounjaro acts on appetite regulation through both GIP and GLP-1 receptors, it has been reported to make it easier to self-regulate food intake
Blood sugar improvement effect
In the SURPASS-2 trial, the HbA1c reduction in the Mounjaro groups (2.01–2.30%) exceeded the reduction in the semaglutide 1 mg group (1.86%)

Precautions when using Mounjaro
With Mounjaro, particular attention is needed to three points: it should not be used during pregnancy or breastfeeding, the risk of pancreatitis, and careful administration in patients with reduced kidney function.
Use during pregnancy and breastfeeding
Its safety during pregnancy and breastfeeding has not been sufficiently established, so its use is not recommended.
Risk of pancreatitis
Pancreatitis is a rare side effect reported for GLP-1 receptor agonists in general. If you have strong abdominal pain, nausea or similar symptoms, seek medical care immediately.
Patients with reduced kidney function
If kidney function is reduced, dose adjustment and close monitoring are necessary.
Reasons to choose Mounjaro
Mounjaro can be a strong option from three perspectives: ease of continuing treatment, weight loss effect and blood sugar improvement. Mounjaro is a better option than other GLP-1 receptor agonists in the following respects.
- Once-weekly dosing makes it easy to continue, with high treatment adherence
- With the addition of GIP action, weight loss through appetite suppression has been clearly shown in clinical trials
- It also has a strong blood sugar–improving effect, with a low risk of hypoglycemia when used alone
Because of these features, it is one option especially for patients with type 2 diabetes seeking obesity treatment and patients with a high BMI. Please note that in Japan, Mounjaro is approved only for the treatment of type 2 diabetes, and its use for weight loss is off-label use and self-pay treatment (the full cost is borne by the patient).
Examples of use in actual clinical practice
In clinical practice, its use is considered in three patterns: patients with obesity with a BMI of 30 or more, patients with type 2 diabetes with inadequate blood sugar control, and patients for whom conventional drugs were not effective enough. In clinical practice, Mounjaro is used effectively in cases such as the following.
Patients with obesity with a BMI of 30 or more
Uses the appetite-suppressing effect to support a manageable reduction in food intake and weight loss
Patients with type 2 diabetes whose blood sugar control is inadequate
Stabilizes blood sugar through promotion of insulin secretion and suppression of glucagon
When weight loss with conventional drugs was insufficient
Makes use of the strength of GIP action to differentiate it from conventional drugs
Would you like to ask a doctor whether Mounjaro could be an option for your condition?
*This is self-pay treatment. Effects and side effects vary from person to person.
About self-pay treatment and off-label use
FAQ
Here are answers to frequently asked questions about the differences between Mounjaro and other GLP-1 receptor agonists.
QIs Mounjaro always more effective than semaglutide?
In the SURPASS-2 trial in patients with type 2 diabetes, Mounjaro showed greater HbA1c reduction and weight loss than semaglutide 1 mg. However, effects vary from person to person, and the most suitable medication differs depending on constitution and medical history.
QWhat changes when a drug acts on both GIP and GLP-1?
Compared with GLP-1-only drugs, clinical trials have reported that adding GIP action tends to strengthen appetite suppression and weight loss. However, the detailed mechanism of why GIP action produces this additional effect is still being researched.
QShould I choose Mounjaro or liraglutide (Saxenda)?
They differ in dosing frequency (Mounjaro once weekly, liraglutide daily) and in the size of the weight loss effect. Which is appropriate depends on your daily routine, constitution and treatment goals, so it is important to decide after consulting your doctor.
QAre the side effects different from other GLP-1 receptor agonists?
Gastrointestinal symptoms such as nausea, constipation and diarrhea are typical side effects reported for GLP-1 drugs in general, including Mounjaro. Although frequency and severity differ by drug, in all cases they tend to appear early in treatment and ease over time.
QIs Mounjaro covered by health insurance in Japan for weight loss?
No. In Japan, Mounjaro is approved as a medication for type 2 diabetes, and its use for weight loss (obesity treatment) is off-label use. It is not covered by health insurance and is self-pay treatment (the full cost is borne by the patient).
Not sure? Talk to us
No consultation fee (first & follow-up visits)Online consultation available
Toll-free 0120-241-929 (toll-free in Japan, 9:00–18:00 JST, Japanese only)
Summary
Mounjaro stands apart from existing GLP-1 receptor agonists in that it acts on two hormones, GIP and GLP-1. With once-weekly dosing, it also has a strong blood sugar–improving effect and may be able to support obesity treatment and diabetes management at the same time.
The difference from other GLP-1 receptor agonists lies in whether or not they have GIP action and the resulting size of the weight loss effect, for which evidence has been shown in clinical trials. It is important to continue treatment safely under a doctor’s supervision while combining it with appropriate lifestyle improvements.
References
All numerical data in this article are based on peer-reviewed clinical trial publications.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Who to contact if you have side effects | When to seek care
If any of the following symptoms occur, please contact us rather than waiting to see on your own. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly gastrointestinal symptoms. Most are mild, but serious ones occur in rare cases.
| Symptom | Possible cause | What to do |
|---|---|---|
| Persistent nausea or vomiting | Gastrointestinal symptoms; the most common side effect | Contact us if you continue to be unable to keep fluids down |
| Severe abdominal pain (pain that radiates to the back) | Possible acute pancreatitis | Stop the medication immediately and seek medical care |
| Cold sweat, palpitations, intense hunger, feeling confused or drowsy | Hypoglycemia | Take sugar right away and contact us |
| Skin rash, difficulty breathing, swelling of the face or throat | Allergic reaction | Seek medical care immediately |
If your symptoms are severe outside these hours, please go to a nearby emergency medical facility.
Direct phone numbers for each clinic are listed on the clinic information page.
References
The information about medications in this article is based on the following official sources. For details on dosage and administration and side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert” (Japanese)
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF, Japanese)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases” (Japanese)
When Mounjaro is used for purposes other than obesity disease, it is self-pay treatment and is not covered by public health insurance. Effects and side effects vary from person to person.
Medically reviewed by: Dr. Hiroko Oka (Chair, Fukubikai Medical Corporation / Certified Member, Japanese Society of Internal Medicine)



